Pfizer reshuffles top leadership to hone commercial strategy, leaving room for new rare disease chief
Some shuffling is taking place at the top ranks of Pfizer.
Longtime exec Andy Schmeltz announced on LinkedIn that he’s moving onto his next tour of duty to helm the newly established Pfizer Commercial Strategy & Innovation (CSI) group, which will be in charge of portfolio strategy and investment decisions. Taking his place leading the oncology unit will be Suneet Varma — a fellow Pfizer vet with almost 22 years at the pharma giant — who’s been appointed as global oncology & US president.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 150,300+ biopharma pros reading Endpoints daily — and it's free.